The results presented at the meeting were from the initial PK study with a total of 60 adults with seasonal allergies. The objective of the study was to compare bioavailability of two proprietary nasal formulations of epinephrine with EpiPen® 0.3 mg in subjects with seasonal allergies with and without allergen challenge. Safety assessments were conducted throughout the study which included physical and nasal exams, adverse event collection, vital signs monitoring, ECG evaluation, and clinical laboratory and olfactory testing. The study results demonstrated that both formulations of epinephrine nasal spray are absorbed rapidly in subjects with and without allergen challenge. All adverse events reported were either mild or moderate in severity. The presented poster may be viewed on the
“These results presented to the scientific community further support the potential for a needleless alternative to the current standard of care and further validates the viability of an intranasal delivery system for epinephrine for the treatment of allergic reactions including anaphylaxis,” said Dr.
The validity of INSYS’ formulation as an alternative to the current standard of care for the treatment of allergic reactions including anaphylaxis was further supported by the Company’s dose finding PK study conducted in
NOTE: All trademarks and registered trademarks are the property of their respective owners.
This news release contains forward-looking statements based on management’s expectations and assumptions as of the date of this news release. Actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risks described in our filings with the
|CONTACT:||Investor Relations & Corporate Communications|
|Jackie Marcus or Chris Hodges|
|Alpha IR Group|
Source: INSYS Therapeutics, Inc.